Biostem Technologies

Biostem Technologies Cash Flow per Share

The Operating Cash Flow per Share of Biostem Technologies (BSEM) as of Nov 19, 2026 is 2.65 USD. In the previous year, Operating Cash Flow per Share was -0.38 USD — a change of -799.54% (higher).

Cash Flow per Share

2.65USD

YoY

-799.54%

Last updated:

Operating Cash Flow per Share of Biostem Technologies is 2024 2.65 USD. Operating Cash Flow per Share of Biostem Technologies was 2023 -0.38 USD. It decreases by -799.54% higher compared to the previous year.

The Biostem Technologies Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2017
-0.80 USD
Jan 1, 2018
-0.38 USD
Jan 1, 2019
-0.09 USD
Jan 1, 2020
-0.06 USD
Jan 1, 2021
-0.01 USD
Jan 1, 2022
-0.18 USD
Jan 1, 2023
-0.38 USD
Jan 1, 2024
2.65 USD
The Biostem Technologies Cash Flow per Share history
YEARCash Flow per ShareYoY
2.65USD-799.54%
-0.38USD+113.75%
-0.18USD+1,395.76%
-0.01USD-81.18%
-0.06USD-31.24%
-0.09USD-76.04%
-0.38USD-51.98%
-0.80USD+392.21%
-0.16USD+322.45%
-0.04USD+90.61%
-0.02USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biostem Technologies Stock analysis

What does Biostem Technologies do? Biostem Technologies Inc is a US company specializing in regenerative medicine. It was founded in 2007 and is based in Clearwater, Florida. Biostem Technologies is listed on the OTCQB Stock Exchange and offers a wide range of products in the field of regenerative medicine. The company's business model primarily involves advancing growth in the field of regenerative medicine through the development and marketing of new products and technologies. They focus on the production of stem cells that can be used in the regeneration of damaged tissues and organs. They also offer research and development of stem cell therapies, manufacturing of stem cell products, and related services. Biostem Technologies places emphasis on processing umbilical cord blood stem cells, collaborating with medical facilities to collect and isolate these cells for preservation. The company has also developed products such as BioStem Serum and BioStem Gel, made from stem cells and used in regeneration and wound healing. They have developed technologies for regenerating damaged tissues and organs, including a technology for regenerating muscle and adipose tissue through stem cell injection. Clinical studies have shown promising results with this technology. Biostem Technologies has partnerships with other companies and institutes in the field of regenerative medicine, including working with the National Institute of Neurological Disorders and Stroke to develop a new therapy for multiple sclerosis. They also provide consulting services to assist other companies in developing regenerative products and services. In conclusion, Biostem Technologies is a leading company in the field of regenerative medicine and stem cell therapies, offering a range of products and services. They also provide important technologies for tissue regeneration, positioning them as a key player in the field of regenerative medicine. Biostem Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biostem Technologies stock

Operating Cash Flow per Share of Biostem Technologies is 2.65 USD in 2024.

Operating Cash Flow per Share of Biostem Technologies changed from -0.38 USD to 2.65 USD, representing a -799.54% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Biostem Technologies since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Biostem Technologies

All Key Metrics — Biostem Technologies